Post-transcriptional regulation in cancer progression Microenvironmental control of alternative splicing and translation

Journal of Cell Communication and Signaling

Volumn 6, Issue 4, 2012, Pages 233-248

  Jewer, Michael ^a   Findlay, Scott D ^a   Postovit, Lynne Marie ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

Alternative splicing; Cancer progression; Translation; Tumor microenvironment

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 2; RAPAMYCIN; VASCULOTROPIN;

ALTERNATIVE RNA SPLICING; ANGIOGENESIS; CANCER CELL; CANCER GROWTH; CELL MIGRATION; DISEASE ASSOCIATION; DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HYPOXIA; MICROENVIRONMENT; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROCESSING; REVIEW; RNA PROCESSING; TRANSLATION INITIATION; TUMOR MICROENVIRONMENT;

EID: 84874114438     PISSN: 18739601     EISSN: 1873961X     Source Type: Journal    
DOI: 10.1007/s12079-012-0179-x     Document Type: Review

References (161)

1. Abcouwer SF, Marjon PL, Loper RK, Vander Jagt DL (2002) Response of VEGF expression to amino acid deprivation and inducers of endoplasmic reticulum stress. Invest Ophthalmol Vis Sci 43:2791-2798
2. Aoki M, Blazek E, Vogt PK (2001) A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A 98:136-141
3. Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, Perlman DM, Manivel JC, Sonenberg N, Yee D, Bitterman PB et al (2004) Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5:553-563
4. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF (1998) CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A 95:6355-6360
5. Bardella C, Costa B, Maggiora P, Patane' S, Olivero M, Ranzani GN, De Bortoli M, Comoglio PM, Di Renzo MF (2004) Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res 64:5154-5161
6. Bates DO, Cui T-G, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ (2002) VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is downregulated in renal cell carcinoma. Cancer Res 62:4123-4131
7. Bedogni B, Powell MB (2009) Hypoxia, melanocytes and melanoma -survival and tumor development in the permissive microenvironment of the skin. Pigment Cell Melanoma Res 22:166-174
8. Bellavia D, Mecarozzi M, Campese AF, Grazioli P, Gulino A, Screpanti I (2007) Notch and Ikaros: not only converging players in T cell leukemia. Cell cycle 6:2730-2734
9. Beltran M, Puig I, Peña C, García JM, Alvarez AB, Peña R, Bonilla F, de Herreros AG (2008) A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelialmesenchymal transition. Genes Dev 22:756-769
10. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, Cordon-Cardo C, Simon MC, Rafii S, Pandolfi PP (2006) PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 442:779-785
11. Bevan HS, van den Akker NMS, Qiu Y, Polman JAE, Foster RR, Yem J, Nishikawa A, Satchell SC, Harper SJ, Gittenberger-de Groot AC et al (2008) The alternatively spliced anti-angiogenic family of VEGF isoforms VEGFxxxb in human kidney development. Nephron Physiol 110:57-67
12. Bielli P, Busa R, Paronetto MP, Sette C (2011) The RNA-binding protein Sam68 is a multifunctional player in human cancer. Endocr Relat Cancer 18:91-102
13. Blaustein M, Pelisch F, Tanos T, Muñoz MJ, Wengier D, Quadrana L, Sanford JR, Muschietti JP, Kornblihtt AR, Cáceres JF et al (2005) Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT. Nat Struct Mol Biol 12:1037-1044
14. Bomsztyk K, Denisenko O, Ostrowski J (2004) hnRNP K: one protein multiple processes. Bioessays 26:629-638
15. Bornes S, Boulard M, Hieblot C, Zanibellato C, Iacovoni JS, Prats H, Touriol C (2004) Control of the vascular endothelial growth factor internal ribosome entry site (IRES) activity and translation initiation by alternatively spliced coding sequences. J Biol Chem 279:18717-18726
16. Catena R, Larzabal L, Larrayoz M, Molina E, Hermida J, Agorreta J, Montes R, Pio R, Montuenga LM, Calvo A (2010) VEGF121b and VEGF165b are weakly angiogenic isoforms of VEGF-A. Mol Cancer 9:320
17. Chang M-L, Chen J-C, Alonso CR, Kornblihtt AR, Bissell DM (2004) Regulation of fibronectin splicing in sinusoidal endothelial cells from normal or injured liver. Proc Natl Acad Sci USA 101:18093-18098
18. Chaudhury A, Chander P, Howe PH (2010a) Heterogeneous nuclear ribonucleoproteins (hnRNPs) in cellular processes: focus on hnRNP E1's multifunctional regulatory roles. RNA 16:1449-1462
19. Chaudhury A, Hussey GS, Ray PS, Jin G, Fox PL, Howe PH (2010b) TGF-beta-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI. Nat Cell Biol 12:286-293
20. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452:230-233
21. Chung J, Bachelder RE, Lipscomb EA, Shaw LM, Mercurio AM (2002) Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells. J Cell Biol 158:165-174
22. Collesi C, Santoro MM, Gaudino G, Comoglio PM (1996) A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol 16:5518-5526
23. Créancier L, Morello D, Mercier P, Prats AC (2000) Fibroblast growth factor 2 internal ribosome entry site (IRES) activity ex vivo and in transgenic mice reveals a stringent tissue-specific regulation. J Cell Biol 150:275-281
24. Dales J-P, Beaufils N, Silvy M, Picard C, Pauly V, Pradel V, Formisano-Tréziny C, Bonnier P, Giusiano S, Charpin C et al (2010) Hypoxia inducible factor 1alpha gene (HIF-1alpha) splice variants: potential prognostic biomarkers in breast cancer. BMC Med 8:44
25. David CJ, Manley JL (2010) Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 24:2343-2364
26. DeFatta RJ, Nathan CO, De Benedetti A (2000) Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. Laryngoscope 110:928-933
27. Di Modugno F, Bronzi G, Scanlan MJ, Del Bello D, Cascioli S, Venturo I, Botti C, Nicotra MR, Mottolese M, Natali PG et al (2004) Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response. Int J Cancer 109:909-918
28. Di Modugno F, Mottolese M, Di Benedetto A, Conidi A, Novelli F, Perracchio L, Venturo I, Botti C, Jager E, Santoni A et al (2006) The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors. Clin Cancer Res 12:1470-1478
29. Eberle J, Krasagakis K, Orfanos CE (1997) Translation initiation factor eIF-4A1 mRNA is consistently overexpressed in human melanoma cells in vitro. Int J Cancer 71:396-401
30. Erler JT, Bennewith KL, Nicolau M, Dornhöfer N, Kong C, Le QT, Chi JT, Jeffrey SS, Giaccia AJ (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440:1222-1226
31. Evdokimova V, Ovchinnikov LP, Sorensen PH (2006) Y-box binding protein 1: providing a new angle on translational regulation. Cell Cycle 5:1143-1147
32. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, Sorokin A, Ovchinnikov LP, Davicioni E, Triche TJ et al (2009) Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelialmesenchymal transition. Cancer Cell 15:402-415
33. Fackenthal JD, Godley LA (2008) Aberrant RNA splicing and its functional consequences in cancer cells. Dis Model Mech 1:37-42
34. Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527-543
35. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J (2002) Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 16:1472-1487
36. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J (2004) mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24:200-216
37. Folkman J, Hanahan D (1991) Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 22:339-347
38. Forristal CE,Wright KL, Hanley NA, Oreffo RO, Houghton FD (2010) Hypoxia inducible factors regulate pluripotency and proliferation in human embryonic stem cells cultured at reduced oxygen tensions. Reproduction 139:85-97
39. Fraser D, Wakefield L, Phillips A (2002) Independent regulation of transforming growth factor-beta1 transcription and translation by glucose and platelet-derived growth factor. Am J Pathol 161:1039-1049
40. Gardner LB (2010) Nonsense-mediated RNA decay regulation by cellular stress: implications for tumorigenesis. Mol Cancer Res 8:295-308
41. Ge Y, Zhou F, Chen H, Cui C, Liu D, Li Q, Yang Z,Wu G, Sun S, Gu J et al (2010) Sox2 is translationally activated by eukaryotic initiation factor 4E in human glioma-initiating cells. Biochem Biophys Res Commun 397:711-717
42. Genolet R, Rahim G, Gubler-Jaquier P, Curran J (2011) The translational response of the human mdm2 gene in HEK293T cells exposed to rapamycin: a role for the 5′-UTRs. Nucleic Acids Res 39:989-1003
43. Ghigna C, Giordano S, Shen H, Benvenuto F, Castiglioni F, Comoglio PM, Green MR, Riva S, Biamonti G (2005) Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Molecular cell 20:881-890
44. Gingras AC, Raught B, Sonenberg N (2001) Regulation of translation initiation by FRAP/mTOR. Genes Dev 15:807-826
45. Görlach A, Camenisch G, Kvietikova I, Vogt L, Wenger RH, Gassmann M (2000) Efficient translation of mouse hypoxiainducible factor-1alpha under normoxic and hypoxic conditions. Biochim Biophys Acta 1493:125-134
46. Goswami S, Philippar U, Sun D, Patsialou A, Avraham J, Wang W, Di Modugno F, Nistico P, Gertler FB, Condeelis JS (2009) Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo. Clin Exp Metastasis 26:153-159
47. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS et al (2007) Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 117:2638-2648
48. Greijer AE, van der Groep P, Kemming D, Shvarts A, Semenza GL, Meijer GA, van de Wiel MA, Belien JAM, van Diest PJ, van der Wall E (2005) Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 206:291-304
49. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
50. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
51. Hang X, Li P, Li Z, Qu W, Yu Y, Li H, Shen Z, Zheng H, Gao Y, Wu Y et al (2009) Transcription and splicing regulation in human umbilical vein endothelial cells under hypoxic stress conditions by exon array. BMC Genom 10:126
52. Harper SJ, Bates DO (2008) VEGF-A splicing: the key to antiangiogenic therapeutics Nat Rev Cancer 8:880-887
53. Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18:1926-1945
54. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4:988-1004
55. Hirschfeld M, Zur Hausen A, Bettendorf H, Jager M, Stickeler E (2009) Alternative splicing of Cyr61 is regulated by hypoxia and significantly changed in breast cancer. Cancer Res 69:2082-2090
56. Holcik M, Sonenberg N (2005) Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 6:318-327
57. Hope NR, Murray GI (2011) The expression profile of RNA-binding proteins in primary and metastatic colorectal cancer: relationship of heterogeneous nuclear ribonucleoproteins with prognosis. Hum Pathol 42:393-402
58. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW (1991) The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806-1814
59. Huang Y, Steitz JA (2005) SRprises along a messenger's journey. Molecular cell 17:613-615
60. Huang C-S, Shen C-Y, Wang H-W, Wu P-E, Cheng C-W (2007) Increased expression of SRp40 affecting CD44 splicing is associated with the clinical outcome of lymph node metastasis in human breast cancer. Clin Chim Acta 384:69-74
61. Huez I, Créancier L, Audigier S, Gensac MC, Prats AC, Prats H (1998) Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA. Mol Cell Biol 18:6178-6190
62. Huez I, Bornes S, Bresson D, Créancier L, Prats H (2001) New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. Mol Endocrinol 15:2197-2210
63. Imai T, Horiuchi A, Wang C, Oka K, Ohira S, Nikaido T, Konishi I (2003) Hypoxia attenuates the expression of E-cadherin via upregulation of SNAIL in ovarian carcinoma cells. Am J Pathol 163:1437-1447
64. Johannes G, Carter MS, Eisen MB, Brown PO, Sarnow P (1999) Identification of eukaryotic mRNAs that are translated at reduced cap binding complex eIF4F concentrations using a cDNA microarray. Proc Natl Acad Sci U S A 96:13118-13123
65. Karbowniczek M, Spittle CS, Morrison T, Wu H, Henske EP (2008) mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 128:980-987
66. Kerekatte V, Smiley K, Hu B, Smith A, Gelder F, De Benedetti A (1995) The proto-oncogene/translation factor eIF4E: a survey of its expression in breast carcinomas. Int J Cancer 64:27-31
67. Kevil CG, De Benedetti A, Payne DK, Coe LL, Laroux FS, Alexander JS (1996) Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int J Cancer 65:785-790
68. Kikuchi H, Pino MS, Zeng M, Shirasawa S, Chung DC (2009) Oncogenic KRAS and BRAF differentially regulate hypoxiainducible factor-1alpha and -2alpha in colon cancer. Cancer Res 69:8499-8506
69. Kireeva ML, Mo FE, Yang GP, Lau LF (1996) Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion. Mol Cell Biol 16:1326-1334
70. Kornblihtt AR (2007) Coupling transcription and alternative splicing. Adv Exp Med Biol 623:175-189
71. Kroczynska B, Kaur S, Platanias LC (2009) Growth suppressive cytokines and the AKT/mTOR pathway. Cytokine 48:138-143
72. Kunz M, Moeller S, Koczan D, Lorenz P, Wenger RH, Glocker MO, Thiesen HJ, Gross G, Ibrahim SM (2003) Mechanisms of hypoxic gene regulation of angiogenesis factor Cyr61 in melanoma cells. J Biol Chem 278:45651-45660
73. Ladomery MR, Harper SJ, Bates DO (2007) Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm. Cancer Lett 249:133-142
74. Lang KJ, Kappel A, Goodall GJ (2002) Hypoxia-inducible factor-1alpha mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia. Mol Biol Cell 13:1792-1801
75. Lazaris-Karatzas A, Montine KS, Sonenberg N (1990) Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 345:544-547
76. Lefave CV, Squatrito M, Vorlova S, Rocco GL, Brennan CW, Holland EC, Pan YX, Cartegni L (2011) Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO J.
77. Lei J, Jiang A, Pei D (1998) Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183. Biochim Biophys Acta 1443:400-406
78. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309
79. Levy C, Khaled M, Fisher DE (2006) MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 12:406-414
80. Lewis TS, Hunt JB, Aveline LD, Jonscher KR, Louie DF, Yeh JM, Nahreini TS, Resing KA, Ahn NG (2000) Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry. Mol Cell 6:1343-1354
81. Li BD, Liu L, Dawson M, De Benedetti A (1997) Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer 79:2385-2390
82. Li S, Takasu T, Perlman DM, Peterson MS, Burrichter D, Avdulov S, Bitterman PB, Polunovsky VA (2003) Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J Biol Chem 278:3015-3022
83. Li CY, Chu JY, Yu JK, Huang XQ, Liu XJ, Shi L, Che YC, Xie JY (2004a) Regulation of alternative splicing of Bcl-x by IL-6, GMCSF and TPA. Cell research 14:473-479
84. Li S, Perlman DM, Peterson MS, Burrichter D, Avdulov S, Polunovsky VA, Bitterman PB (2004b) Translation initiation factor 4E blocks endoplasmic reticulum-mediated apoptosis. J Biol Chem 279:21312-21317
85. Liao D, Johnson RS (2007) Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 26:281-290
86. Lin MT, Kuo IH, Chang CC, Chu CY, Chen HY, Lin BR, Sureshbabu M, Shih HJ, Kuo ML (2008) Involvement of hypoxia-inducing factor-1alpha-dependent plasminogen activator inhibitor-1 upregulation in Cyr61/CCN1-induced gastric cancer cell invasion. J Biol Chem 283:15807-15815
87. Liu L, Cash TP, Jones RG, Keith B, Thompson CB, Simon MC (2006) Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell 21:521-531
88. Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM, Misteli T (2010) Regulation of alternative splicing by histone modifications. Science (New York, NY) 327:996-1000
89. Luco RF, Allo M, Schor IE, Kornblihtt AR, Misteli T (2011) Epigenetics in Alternative Pre-mRNA Splicing. Cell 144:16-26
90. Lynch KW (2007) Regulation of alternative splicing by signal transduction pathways. Adv Exp Med Biol 623:161-174
91. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N (2006) mTOR, translation initiation and cancer. Oncogene 25:6416-6422
92. Martin MM, Buckenberger JA, Knoell DL, Strauch AR, Elton TS (2006) TGF-beta(1) regulation of human AT(1) receptor mRNA splice variants harboring exon 2. Mol Cell Endocrinol 249:21-31
93. Matter N, Herrlich P, König H (2002) Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 420:691-695
94. Michlewski G, Sanford JR, Cáceres JF (2008) The splicing factor SF2/ASF regulates translation initiation by enhancing phosphorylation of 4E-BP1. Molecular cell 30:179-189
95. Miyagi Y, Sugiyama A, Asai A, Okazaki T, Kuchino Y, Kerr SJ (1995) Elevated levels of eukaryotic translation initiation factor eIF-4E,mRNA in a broad spectrum of transformed cell lines. Cancer Lett 91:247-252
96. Moller-Levet CS, Betts GNJ, Harris AL, Homer JJ, West CML, Miller CJ (2009) Exon array analysis of head and neck cancers identifies a hypoxia related splice variant of LAMA3 associated with a poor prognosis. PLoS Comput Biol 5:e1000571
97. Mukudai Y, Kubota S, Eguchi T, Sumiyoshi K, Janune D, Kondo S, Shintani S, Takigawa M (2010) A coding RNA segment that enhances the ribosomal recruitment of chicken ccn1 mRNA. J Cell Biochem 111:1607-1618
98. Nasr Z, Robert F, Porco JA Jr., Muller WJ, Pelletier J (2012) eIF4F suppression in breast cancer affects maintenance and progression. Oncogene.
99. Nathan CO, Carter P, Liu L, Li BD, Abreo F, Tudor A, Zimmer SG, De Benedetti A (1997) Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas. Oncogene 15:1087-1094
100. Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, Harper SJ, Bates DO (2008) Expression of pro-and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci 121:3487-3495
101. Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara M, Harper SJ, Woolard J, Ladomery MR et al (2010) Regulation of Vascular Endothelial Growth Factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem 285:5532-5540
102. O'Kelly J, Chung A, Lemp N, Chumakova K, Yin D, Wang HJ, Said J, Gui D, Miller CW, Karlan BY et al (2008) Functional domains of CCN1 (Cyr61) regulate breast cancer progression. Int J Oncol 33:59-67
103. O'Reilly KE, Warycha M, Davies MA, Rodrik V, Zhou XK, Yee H, Polsky D, Pavlick AC, Rosen N, Bhardwaj N et al (2009) Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin Cancer Res 15:2872-2878
104. Oltean S, Sorg BS, Albrecht T, Bonano VI, Brazas RM, Dewhirst MW, Garcia-Blanco MA (2006) Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc Natl Acad Sci USA 103:14116-14121
105. Patel NA, Kaneko S, Apostolatos HS, Bae SS, Watson JE, Davidowitz K, Chappell DS, Birnbaum MJ, Cheng JQ, Cooper DR (2005) Molecular and genetic studies imply Akt-mediated signaling promotes protein kinase CbetaII alternative splicing via phosphorylation of serine/arginine-rich splicing factor SRp40. J Biol Chem 280:14302-14309
106. Perbal B (2009) Alternative splicing of CCN mRNAs .... it has been upon us. J Cell Commun Signal 3:153-157
107. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N (2007) mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 96:R11-R15
108. Philippar U, Roussos ET, Oser M, Yamaguchi H, Kim H-D, Giampieri S, Wang Y, Goswami S, Wyckoff JB, Lauffenburger DA et al (2008) A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev Cell 15:813-828
109. Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E, Neufeld G (1997) VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 272:7151-7158
110. Pond AC, Herschkowitz JI, Schwertfeger KL, Welm B, Zhang Y, York B, Cardiff RD, Hilsenbeck S, Perou CM, Creighton CJ et al (2010) Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Res 70:4868-4879
111. Pópulo H, Soares P, Rocha AS, Silva P, Lopes JM (2010) Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res 20:107-117
112. Postovit L-M, Margaryan NV, Seftor EA, Hendrix MJC (2008) Role of nodal signaling and the microenvironment underlying melanoma plasticity. Pigment Cell Melanoma Res 21:348-357
113. Primot A, Mogha A, Corre S, Roberts K, Debbache J, Adamski H, Dreno B, Khammari A, Lesimple T, Mereau A et al (2010) ERKregulated differential expression of the Mitf 6a/b splicing isoforms in melanoma. Pigment Cell Melanoma Res 23:93-102
114. Pritchard-Jones RO, Dunn DBA, Qiu Y, Varey AHR, Orlando A, Rigby H, Harper SJ, Bates DO (2007) Expression of VEGFxxxb, the inhibitory isoforms of VEGF, in malignant melanoma. Br J Cancer 97:223-230
115. Remy I, Montmarquette A, Michnick SW (2004) PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. Nat Cell Biol 6:358-365
116. Rennel ES, Waine E, Guan H, Schüler Y, Leenders W, Woolard J, Sugiono M, Gillatt D, Kleinerman ES, Bates DO et al (2008) The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer 98:1250-1257
117. Ria R, Reale A, Castrovilli A, Mangialardi G, Dammacco F, Ribatti D, Vacca A (2010) Angiogenesis and progression in human melanoma. Dermatol Res Pract 2010:185687
118. Riley A, Jordan LE, Holcik M (2010) Distinct 5UTRs regulate XIAP expression under normal growth conditions and during cellular stress. Nucleic Acids Res 38:4665-4674
119. Rofstad EK, Rasmussen H, Galappathi K, Mathiesen B, Nilsen K, Graff BA (2002) Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res 62:1847-1853
120. Rosenwald IB, Wang S, Savas L, Woda B, Pullman J (2003) Expression of translation initiation factor eIF-2alpha is increased in benign and malignant melanocytic and colonic epithelial neoplasms. Cancer 98:1080-1088
121. Rousseau D, Gingras AC, Pause A, Sonenberg N (1996) The eIF4Ebinding proteins 1 and 2 are negative regulators of cell growth. Oncogene 13:2415-2420
122. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M (2011) Global quantification of mammalian gene expression control. Nature 473:337-342
123. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721-732
124. Shapiro IM, Cheng AW, Flytzanis NC, Balsamo M, Condeelis JS, Oktay MH, Burge CB, Gertler FB (2011) An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet 7:e1002218
125. Shirakihara T, Horiguchi K, Miyazawa K, Ehata S, Shibata T, Morita I, Miyazono K, Saitoh M (2011) TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition. EMBO J 30:783-795
126. Shuda M, Kondoh N, Tanaka K, Ryo A, Wakatsuki T, Hada A, Goseki N, Igari T, Hatsuse K, Aihara T et al (2000) Enhanced expression of translation factor mRNAs in hepatocellular carcinoma. Anticancer Res 20:2489-2494
127. Shultz JC, Goehe RW,Wijesinghe DS, Murudkar C, Hawkins AJ, Shay JW, Minna JD, Chalfant CE (2010) Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Res 70:9185-9196
128. Sodhi A, Chaisuparat R, Hu J, Ramsdell AK, Manning BD, Sausville EA, Sawai ET, Molinolo A, Gutkind JS, Montaner S (2006) The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G proteincoupled receptor. Cancer Cell 10:133-143
129. Srebrow A, Kornblihtt AR (2006) The connection between splicing and cancer. J Cell Sci 119:2635-2641
130. Stamm S (2002) Signals and their transduction pathways regulating alternative splicing: a new dimension of the human genome. Hum Mol Genet 11:2409-2416
131. Stein I, Itin A, Einat P, Skaliter R, Grossman Z, Keshet E (1998) Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. Mol Cell Biol 18:3112-3119
132. Stephens L, Williams R, Hawkins P (2005) Phosphoinositide 3-kinases as drug targets in cancer. Curr Opin Pharmacol 5:357-365
133. Stoneley M, Willis AE (2004) Cellular internal ribosome entry segments: structures, trans-acting factors and regulation of gene expression. Oncogene 23:3200-3207
134. Tacconelli A, Farina AR, Cappabianca L, Desantis G, Tessitore A, Vetuschi A, Sferra R, Rucci N, Argenti B, Screpanti I et al (2004) TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell 6:347-360
135. Tan A, Bitterman P, Sonenberg N, Peterson M, Polunovsky V (2000) Inhibition of Myc-dependent apoptosis by eukaryotic translation initiation factor 4E requires cyclin D1. Oncogene 19:1437-1447
136. Tanaka S, Sugimachi K, Saeki H, Kinoshita J, Ohga T, Shimada M, Maehara Y (2001) A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma. Oncogene 20:5525-5532
137. Thiery JP, Acloque H, Huang RYJ, Nieto MA (2009) Epithelialmesenchymal transitions in development and disease. Cell 139:871-890
138. Thomassen M, Blanco A, Montagna M, Hansen TV, Pedersen IS, Gutierrez-Enriquez S, Menendez M, Fachal L, Santamarina M, Steffensen AY, et al (2011) Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members. Breast Cancer Res Treat.
139. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947-11954
140. Uniacke J, Holterman CE, Lachance G, Franovic A, Jacob MD, Fabian MR, Payette J, Holcik M, Pause A, Lee S (2012) An oxygenregulated switch in the protein synthesis machinery. Nature 486:126-129
141. Vagner S, Gensac MC, Maret A, Bayard F, Amalric F, Prats H, Prats AC (1995) Alternative translation of human fibroblast growth factor 2 mRNA occurs by internal entry of ribosomes. Mol Cell Biol 15:35-44
142. Valacca C, Bonomi S, Buratti E, Pedrotti S, Baralle FE, Sette C, Ghigna C, Biamonti G (2010) Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene. J Cell Biol 191:87-99
143. Villanueva J, Herlyn M (2008) Melanoma and the tumor microenvironment. Curr Oncol Rep 10:439-446
144. Wagner JA (1991) The fibroblast growth factors: an emerging family of neural growth factors. Curr Top Microbiol Immunol 165:95-118
145. Wang WB, Boing S, Zhou XQ, Ji P, Dong Y, Yao Q, Muller-Tidow C (2002) Identification of metastasis-associated genes in early stage non-small cell lung cancer by subtractive hybridization. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 34:273-278
146. Wang W, Goswami S, Lapidus K, Wells AL, Wyckoff JB, Sahai E, Singer RH, Segall JE, Condeelis JS (2004) Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res 64:8585-8594
147. Wang W, Wyckoff JB, Goswami S, Wang Y, Sidani M, Segall JE, Condeelis JS (2007) Coordinated regulation of pathways for enhanced cell motility and chemotaxis is conserved in rat and mouse mammary tumors. Cancer Res 67:3505-3511
148. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB (2008) Alternative isoform regulation in human tissue transcriptomes. Nature 456:470-476
149. Wang X, Zhao Y, Xiao Z, Chen B, Wei Z, Wang B, Zhang J, Han J, Gao Y, Li L et al (2009) Alternative translation of OCT4 by an internal ribosome entry site and its novel function in stress response. Stem Cells 27:1265-1275
150. Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP (2009a) ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell 33:591-601
151. Warzecha CC, Shen S, Xing Y, Carstens RP (2009b) The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events. RNA Biol 6:546-562
152. Watermann DO, Tang Y, Zur Hausen A, Jäger M, Stamm S, Stickeler E (2006) Splicing factor Tra2-beta1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene. Cancer Res 66:4774-4780
153. Wen F, Shen A, Shanas R, Bhattacharyya A, Lian F, Hostetter G, Shi J (2010) Higher expression of the heterogeneous nuclear ribonucleoprotein k in melanoma. Ann Surg Oncol 17:2619-2627
154. White ES, Sagana RL, Booth AJ, Yan M, Cornett AM, Bloomheart CA, Tsui JL, Wilke CA, Moore BB, Ritzenthaler JD et al (2010) Control of fibroblast fibronectin expression and alternative splicing via the PI3K/Akt/mTOR pathway. Exp Cell Res 316:2644-2653
155. Winter SC, Buffa FM, Silva P, Miller C, Valentine HR, Turley H, Shah KA, Cox GJ, Corbridge RJ, Homer JJ et al (2007) Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 67:3441-3449
156. Woolard J, Wang W-Y, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, Cui T-G, Sugiono M, Waine E, Perrin R et al (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 64:7822-7835
157. Wouters BG, Koritzinsky M (2008) Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8:851-864
158. Yan G, Fukabori Y, McBride G, Nikolaropolous S, McKeehan WL (1993) Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 13:4513-4522
159. Yang SX, Hewitt SM, Steinberg SM, Liewehr DJ, Swain SM (2007) Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. Oncol Rep 17:281-287
160. Yin JY, Dong Z, Liu ZQ, Zhang JT (2011) Translational control gone awry: a new mechanism of tumorigenesis and novel targets of cancer treatments. Biosci Rep 31:1-15
161. Young RM, Wang SJ, Gordan JD, Ji X, Liebhaber SA, Simon MC (2008) Hypoxia-mediated selective mRNA translation by an internal ribosome entry site-independent mechanism. J Biol Chem 283:16309-16319